KLW-L9-Nala

General Information


DRACP ID  DRACP02532

Peptide Name   KLW-L9-Nala

Sequence  KWKKLLKKXLKLLKKLLK

Sequence Length  18

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A549 Lung adenocarcinoma Carcinoma IC50=2 µM SRB assay 3 days 1
SK-OV-3 Ovarian serous cystadenocarcinoma Carcinoma IC50=1.7 µM SRB assay 3 days 1
SK-MEL-2 Melanoma Carcinoma IC50=2.1 µM SRB assay 3 days 1

Hemolytic Activity  Human erythrocytes: 5% Hemolysis=100 µM

Normal (non-cancerous) Cytotoxicity  NIH 3T3: IC50=7.1 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  X=NAla

Chiral  L



Physicochemical Information


Formula  C107H195N27O17

Absent amino acids  ACDEFGHIMNPQRSTVY

Common amino acids  K

Mass  254532

Pl  11.7

Basic residues  9

Acidic residues  0

Hydrophobic residues  8

Net charge  9

Boman Index  -1318

Hydrophobicity  -52.22

Aliphatic Index  151.67

Half Life 
  /

Extinction Coefficient cystines  5500

Absorbance 280nm  323.53

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 16142907

Title  Cell selectivity and mechanism of action of antimicrobial model peptides containing peptoid residues

Doi 10.1021/bi050765p

Year  2005

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_5219

DRACP is developed by Dr.Zheng's team.